The short version of melanocortin agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-20. Anything still debated is marked as such rather than presented as settled.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
| Property | Value | Notes |
|---|---|---|
| Primary target | Melanocortin receptors | Mainly the MC4R subtype |
| Route of administration | Injection | Typically subcutaneous |
| Time to peak | About 60 minutes | After subcutaneous dosing |
| Elimination half-life | Roughly 2 to 3 hours | Values vary across reports |
| Metabolic pathway | Peptidase hydrolysis | Cleared by the kidneys |
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
=== Special populations === Patients already suffering from debilitation are at a much higher risk of respiratory depression. Non-opioid analgesics should be considered in this population. Elderly patients are much more sensitive to adverse effects such as falls, cognitive impairment and constipation, and should be monitored for such. Decreased renal function associated with aging leads to decreased clearance of the drug, resulting in narrow therapeutic windows and increasing the danger of overdose. If oxymorphone is absolutely indicated, smaller initial doses should be started for this population. There is a risk of neonatal withdrawal symptom in the newborn if pregnant women take oxymorphone for a prolonged period. Oxymorphone crosses the placenta and holds risk of birth defects, poor fetal growth, stillbirth, and preterm delivery. The children of mothers who are physically dependent on oxymorphone have a higher risk of similar dependence. Due to these severe risks, oxymorphone is highly discouraged among this population. The amount of transfer of oxymorphone into the breast milk is not known and women are cautioned to weigh the risks and benefits before breastfeeding while on this medication.
A series of related techniques for determining the age at which a geomorphic surface was created (exposure dating), or at which formerly surficial materials were buried (burial dating). Exposure dating uses the concentration of exotic nuclides (e.g. 10Be, 26Al, 36Cl) produced by cosmic rays interacting with Earth materials as a proxy for the age at which a surface, such as an alluvial fan, was created. Burial dating uses the differential radioactive decay of 2 cosmogenic elements as a proxy for the age at which a sediment was screened by burial from further cosmic rays exposure.
==== Stress and addiction ==== Stress contributes to both the development and the persistence of addiction, affecting neurophysiological pathways, decision-making and relapse risk. Acute and chronic stress activate the hypothalamic–pituitary–adrenal axis, raising levels of cortisol and corticotropin-releasing hormone; these changes alter reward processing and increase the motivational pull of substances, particularly those that temporarily relieve negative mood. In animal studies, repeated stress exposure increases dopamine release in the nucleus accumbens and sensitizes the mesolimbic reward system, making drugs more reinforcing. Chronic stress also disturbs glutamatergic signaling in the prefrontal cortex, impairing inhibitory control and self-regulation, which increases susceptibility to compulsive drug seeking and reduces the ability to disregard drug-associated cues. Stress is among the more reliable predictors of relapse. In human neuroimaging studies, stress-induced activation of the amygdala together with reduced prefrontal regulation is associated with self-reported craving and with subsequent return to use. People with a history of trauma, or of chronic social stress such as discrimination, poverty or housing insecurity, are at increased risk of substance use disorders. Because stress interacts with reward circuitry and decision-making systems, many treatment approaches incorporate stress-reduction strategies, including cognitive behavioral therapy, mindfulness-based interventions and medications acting on stress-related neurochemistry.
Sources: en.wikipedia.org
=== Importance === GGC is essential to mammalian life. Mice that have had the glutamate-cysteine ligase (GCL) gene knocked out do not develop beyond the embryo stage and die before birth. This is because GGC is vital for the biosynthesis of glutathione. Since the production of cellular GGC in humans slows down with age, as well as during the progression of many chronic diseases, it has been postulated that supplementation with GGC could offer health benefits. Such GGC supplementation may also be of benefit in situations where glutathione has been acutely lowered below optimum, such as following strenuous exercise, during trauma or episodes of poisoning. Several review articles have been published exploring the therapeutic potential of GGC to replenish glutathione in age-related and chronic disease states such as Alzheimer's disease. GGC also shows antioxidant properties.
=== Chronic hand eczema === Alitretinoin has been granted prescription rights in the UK (08/09/2008) for in chronic hand eczema as used by mouth. In May 2009 the National Institute for Health and Clinical Excellence (NICE) issued preliminary guidance on the use of alitretinoin for the treatment of severe chronic hand eczema in adults. The recommendation stated that only patients with severe chronic hand eczema who are unresponsive to potent topical corticosteroids, oral immunosuppressants or phototherapy should receive the drug. Final NICE guidance was expected in August 2009.
Due to the arrangement of the receiver antennas, the sensitive area had a number of side lobes that allowed reception at multiple vertical angles. Typically the operator would use the upper set of antennas at 215 ft (66 m), which had the clearest view of the horizon. Due to the half-wave interference from the ground, the main lobe from this antenna was directed at about 2.5 degrees above the horizontal, with its sensitive region extending from about 1 to 3 degrees. At the ground the gain was zero, which allowed aircraft to escape detection by flying at low altitudes. The second lobe extended from about 6 to 12 degrees, and so on. This left a distinct gap in the reception pattern centred at about 5.2 degrees. This reception pattern provided CH with a relatively accurate way to estimate the altitude of the target. To do this, the motorized switch in the receiver hut was used to disconnect the four receiver masts and instead select the two vertically displaced antennas on one mast. When connected to the radiogoniometer, the output on the display was now effected by the relative signal strength of the two lobes, rather than the relative strengths in X and Y in the horizontal plane. The operator swung the radiogoniometer looking for the peak or minimum reception, as before, and noted the angle. The number reported by the operator was the line-of-sight range to the target, or slant range, which included components of both the horizontal distance and altitude.
=== Pink pepper and other plants === Pink peppercorns are the fruits of the Peruvian pepper tree, Schinus molle, or its relative, the Brazilian pepper tree, Schinus terebinthifolius, plants from a different family (Anacardiaceae). As they are members of the cashew family, they may cause allergic reactions, including anaphylaxis, for persons with a tree nut allergy. The bark of Drimys winteri ("canelo" or "winter's bark") is used as a substitute for pepper in cold and temperate regions of Chile and Argentina, where it is easily found and readily available. In New Zealand, the seeds of kawakawa (Piper excelsum), a relative of black pepper, are sometimes used as pepper; the leaves of Pseudowintera colorata ("mountain horopito") are another replacement for pepper. Several plants in the United States are also used as pepper substitutes, such as field pepperwort, least pepperwort, shepherd's purse, horseradish, and field pennycress.
Sources: en.wikipedia.org
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.
It activates pigmentation-related receptors more weakly. This selectivity is thought to alter its side effect profile.
Injection is the most common route. Nasal administration has been studied as well, though absorption varies considerably.
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.